Ultivue om deel te nemen aan de Stifel 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ultivue, een marktleider in multiplextools voor weefselbiomarkeranalyse, zal deelnemen aan de Stifel 2021 Virtual Healthcare Conference, die zal worden gehouden van 15 tot 17 november 2021. De conferentie omvat presentaties en innovatieve paneldiscussies georganiseerd door senior leiderschap in de gezondheidszorg.
Ultivue’s President en Chief Executive Officer, Jacques Corriveau, en Chief Financial Offer, Richard C. Malabre, zullen op 17 november om 9.20 uur ET presenteren. Geïnteresseerde partijen kunnen naar de presentatie luisteren via de volgende link: Ultivue Stifel-presentatie
“We kijken ernaar uit om investeerders te ontmoeten en onze visie te delen voor aanhoudende snelle groei en opwindende nieuwe producten. Ultivue loopt voorop op het gebied van innovatie voor op weefsel gebaseerde testen en biedt kritische inzichten aan onderzoekers en pathologen uit kostbare monsters”, aldus Jacques Corriveau, President en CEO.
Ultivue to Participate in the Stifel 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, will participate in the Stifel 2021 Virtual Healthcare Conference to be held November 15th – 17, 2021. The conference incorporates presentations and innovative panel discussions hosted by senior leadership in the health care industry.
Ultivue’s President and Chief Executive Officer, Jacques Corriveau, and Chief Financial Offer, Richard C. Malabre, will present at 9:20 am ET on November 17. Interested parties may listen to the presentation using the following link: Ultivue Stifel Presentation
“We look forward to meeting investors and sharing our vision for continued rapid growth and exciting new products. Ultivue is at the forefront of innovation for tissue-based assays providing critical insights to researchers and pathologists from precious samples” said Jacques Corriveau, President and CEO.
About Ultivue
Ultivue provides researchers in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
About Stifel
Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. The Company’s broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities.
Stifel hosts several client conferences and events each year, attracting top institutional investors as well as leading companies in their sectors of focus.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005893/en/
Contacts
Richard C. Malabre
Chief Financial Officer
+1 617.710.1341
Adrian Arechiga Ph.D.
VP Marketing
+49 176 3039 0757